TRANSLATE

Thursday, 15 August 2013

ANTI-CANCER DRUG REVERSES ALZHEIMER´S DISEASE IN MICE


The study, published in the journal Science, examined previously published outcomes on the drug bexarotene - which is approved by the U.S. Food and Drug Administration for use in cutaneous T cell lymphoma.
The researchers established that the drug does notably improve cognitive deficits in mice expressing gene mutations associated with human Alzheimer's disease, however, they could not verify the effect on amyloid plaques.
Senior author Rada Koldamova, M.D., Ph.D., associate professor in Pitt Public Health's Department of Environmental and Occupational Health, said, "We believe these findings make a solid case for continued exploration of bexarotene as a therapeutic treatment for Alzheimer's disease."
Dr. Koldamova and her team were studying mice expressing human Apolipoprotein E4 (APOE4) - the only known genetic risk factor for late-onset Alzheimer's disease, or APOE3 - known not to raise the risk for Alzheimer's disease - when a Case Western Reserve University study was published last year.
It claimed that bexarotene elevates memory and rapidly cleared amyloid plaques from the brains of Alzheimer's model mice expressing mouse Apolipoprotein E (APOE).
Amyloid plaques are made up of toxic protein fragments known as amyloid beta that are known to damage neurons in the brain and are believed to result in the memory deficits linked to Alzheimer's disease, and eventually death.
Bexarotene is a compound chemically associated with vitamin A that triggers Retinoic X Receptors (RXR) found all over the body including neurons and other brain cells. Once they are activated, the receptors bind to DNA and control the expression of genes that guide many different biological functions.
Elevated levels of APOE are one result of RXR activations by bexarotene. The researchers started examining similar compounds over 10 years ago.
Source: Medical News Today

No comments:

Post a Comment